Notice Number: NOT-CA-13-017
Release Date: September 12, 2013
Response Date: November 1, 2013
National Cancer Institute (NCI)
The purpose of this Request for Information (RFI) is to gain feedback, comments, and novel ideas from interested members of the cancer nanotechnology community, other relevant segments of scientific communities, and the American public on the field of cancer-relevant nanotechnology including its support by NCI.
This RFI is for information and planning purposes only and should not be construed as a solicitation or as an obligation on the part of the Federal Government, the National Institutes of Health (NIH), and/or the National Cancer Institute (NCI).
The NCI supports the development of nanotechnologies with applications in the diagnosis and therapy of cancer. The Alliance for Nanotechnology in Cancer - a funding program supporting a diverse network of basic and translational researchers - was formed to accomplish this task. Beyond the Alliance efforts, NCI and other Institutes and Centers (ICs) of the NIH support a large portfolio of center awards and individual investigator awards involving nanotechnology.
Biomedical nanotechnology, including cancer-relevant nanotechnology, is widely viewed as a promising and highly innovative field, with a potential for transformative scientific advancements and practical applications. Essential for the realization of this potential is the diversity of scientists and engineers contributing to research and development efforts in biomedical nanotechnology. Thorough understanding of these aspects, including the perspective of the involved members of scientific community is needed for the optimized planning of future initiatives in the field of cancer-relevant medical nanotechnology.
Specifically, the NCI requests that cancer researchers, clinicians, and other interested members of the community share their perspectives on any applicable/relevant aspects in the following areas:
Areas Relevant to Nanotechnology Research
Areas Relevant to Training in Nanotechnology
Areas Related to Commercial Development of Nanotechnology-based Approaches
Comments on other aspects of cancer-related nanotechnology are also welcomed.
Note: Do not include any proprietary or confidential information.
Responses will be accepted through November 1, 2013. Please mark responses with this RFI identifier NOT-CA-13-017. Responses in electronic formats are preferred and can be emailed to firstname.lastname@example.org.
All individual responses will remain confidential. Any identifiers (e.g., names, institutions, e-mail addresses, etc.) will be removed when responses are compiled. Only the processed, anonymized results will be shared internally with NIH staff members and members of scientific working groups convened by the NCI, as appropriate.Respondents will receive an automated email confirmation acknowledging receipt of their response but will not receive any individualized feedback.
Inquiries regarding this RFI should be directed to:
Lynn C. Hull, Ph.D.
Office of Cancer Nanotechnology Research
National Cancer Institute
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.